Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.77 |
| ▸ | S1PR1 | P21453 | 16/20 | 0.76 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19481519 | 1.00 | FAAH (0.77) | FAAHS1PR1S1PR3 | |
| SCHEMBL17309390 | 0.89 | FAAH (0.78) | FAAHS1PR1S1PR3 | |
| SCHEMBL22386385 | 0.88 | FAAH (0.63) | FAAHS1PR1S1PR3 | |
| SCHEMBL17309398 | 0.87 | FAAH (1.00) | FAAHS1PR1S1PR3 | |
| SCHEMBL19481517 | 0.87 | FAAH (1.00) | FAAHS1PR1S1PR3 | |
| SCHEMBL17309391 | 0.86 | FAAH (1.00) | FAAHS1PR1S1PR3 | |
| SCHEMBL17309368 | 0.86 | FAAH (1.00) | FAAHS1PR1S1PR3 | |
| SCHEMBL17309379 | 0.85 | FAAH (0.70) | FAAHS1PR1S1PR3 | |
| SCHEMBL19481522 | 0.83 | FAAH (0.84) | FAAHS1PR1S1PR3 | |
| SCHEMBL19485870 | 0.83 | FAAH (0.84) | FAAHS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148541-B1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | UNIVERSITAT BERN (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-2952188-A1 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | Universität Bern (CH) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015181336-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | SLC18A2, AANAT, CNR2 | FAAH 27/4885S1PR1 848/4885S1PR3 787/4885 |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | SLC18A2, AANAT, CNR2 | FAAH 27/4885S1PR1 848/4885S1PR3 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.